Clinical Trial Search

Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants

Primary: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) — 10; 7; 9; 6 Participants

Primary: Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12 — 12.1; 31.6; 21.8 Percentage of Participants — p=0.0142

Primary: Percentage of Patients Who Achieved Clinical Response — 57; 35 percentage of patients — p=0.05

Primary: Number of Participants With Improvement of Signs and Symptoms of UC at 12 Weeks — 23; 12 participants — p=.005

Primary: Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement/Number of Subjects Evaluated x 100) — 31.4; 24.1; 44.4; 30.0 percentage of participants

Primary: Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score. — 7; 12 Participants — p=0.106

Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants

Primary: Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C) — 30; 26; 14; 41 participants — p=0.124

Primary: Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories — 9.1; 3.4; 10.5; 13.0 Percentage of participants

Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants

Primary: Proportion of Participants With Clinical Remission Per Mayo Score at Week 8 — 9.2; 10.0; 18.5 Proportion of participants — p=0.031

Primary: Percentage of Participants Who Achieved Remission — 38.3; 25.8 percentage of participants — p=0.0324

Primary: Percentage of Participants Who Achieved Remission — 44.0; 22.4 percentage of participants — p=<0.0001

Primary: Incidence of Treatment Emergent AEs — 273 participants

Primary: Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS) — 26.0; 18.3 Percentage of participants — p=0.2524

Primary: Number of Participants With Adverse Events — 3 Participants

Primary: Number of Participants With a Clinical Response at Week 8 — 33; 45; 30 Participants

Primary: Percentage of Patients Achieving Clinical Remission at Week 54 — 127; 30 Participants — p=<0.0001

Primary: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 — 16.5; 9.3 Percentage of Participants — p=0.019

Primary: Number of Subjects With Treatment-emergent Adverse Events — 18; 5 Participants — p=0.2096

Primary: Percentage of Participants Achieving Clinical Remission at Week 12 — 27.0; 7.4 Percentage of participants — p=<0.001

Primary: Clinical Remission — 5; 2; 9; 4 Participants — p=0.1806

Primary: Part A: Number of Participants With Common (>=5%) Non-serious Adverse Events (Non-SAEs) and Any Serious Adverse Events (SAEs) — 7; 13; 1; 0 Participants

Primary: Active Phase: Proportion of Active Subjects Achieving Overall Improvement — 64.1; 69.2 percentage of participants

Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…

Primary: To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC). — 42; 29 participants — p=0.069

Primary: Proportion of Subjects With Remission — 19; 13 Participants — p=>0.05

Primary: Number of Subjects With Treatment-related Adverse Events — 5; 7; 7; 14 Participants

Primary: Percentage of Participants With a Clinical Response — 53; 44 percentage of participants